1 mL BAC
2.5 units
resulting U-100 draw
- Concentration
- 2 mg/mL
- BAC added
- 1 mL
SingleInvestigationalEarly HumanLow confidenceSourced
VIP
A vasoactive neuropeptide studied through intravenous, inhaled and other specialist routes. Rapid haemodynamic effects make route and monitoring central.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
A community-provenance subcutaneous line from an authenticated research forum - low initial quantities because VIP flushes fast, then a nightly build toward ~150 mcg. Intranasal use is at least as common; this line is subcutaneous only and not validated.
Reported maximum quantity
Low then nightly (forum)
Choose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.Reported quantities by phase
Select a point for its calculation examples- Low initial dose (flush test)50 mcgReports open near 50-100 mcg because VIP is a fast vasodilator; 500 mcg first doses were repeatedly called too much.
- Nightly maintenance150 mcg+100 mcgNightly subcutaneous reports cluster around 125-200 mcg; heavier users work up toward 750 mcg per day.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 50 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
3 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw7.5 U
20-30 U reference band
2 mL BAC
5 units
resulting U-100 draw
- Concentration
- 1 mg/mL
- BAC added
- 2 mL
3 mL BAC
7.5 units
resulting U-100 draw
- Concentration
- 0.667 mg/mL
- BAC added
- 3 mL
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Human StudyInhaledSingle exposure
Twenty adults with chronic pulmonary hypertension during catheterisation
A single 100 mcg inhaled aviptadil exposure was evaluated with haemodynamic and blood-gas measurements
This was a monitored acute physiology study, not a subcutaneous protocol or an established general treatment schedule.
View sourceHuman StudyIntravenous infusionDaily for 3 days
Hospitalised adults in the TESICO trial
Aviptadil was infused for 12 hours daily for three days at 600, 1,200 and 1,800 pmol/kg on successive days
This hospital infusion schedule was indication-specific and did not establish benefit for a general or self-directed VIP protocol.
View sourceCommunity GuideIntranasal in reportsSometimes multiple times daily; no cycle stated
online research community sleep reports
Reports use 50-200 mcg per administration, usually intranasally and sometimes multiple times daily
The timing is justified in-channel by a very short quoted half-life, but no cycle length or controlled sleep protocol is supplied. These reports are not transferable from the monitored inhaled or intravenous studies; raw/peptide-education/pe-circadian-rhythm-epitalon.md:47-61.
View sourceCommunity GuideSubcutaneous or intranasal in reportsUsually evening or nightly; sometimes twice daily
authenticated research-forum (Peppys) sleep, respiratory and autoimmune reports
Subcutaneous evening dosing typically begins near 50-100 mcg and builds to about 125-200 mcg nightly, with heavier users reaching up to 750 mcg per day or 500 mcg three times daily; intranasal use is at least as common, described separately as roughly 50 mcg per spray up to four times daily in a 12 mL applicator at 50 mcg/mL, tapered toward zero over 30-90 days
Forum provenance from an authenticated archive with usernames omitted. VIP is described as a fast-acting vasodilator, so reports emphasise low initial quantities and blood-pressure monitoring; quantities conflict and an emerging cancer caveat led some to stop. Subcutaneous, intranasal and nebulised routes are kept separate rather than interconverted.
View sourceEvidence summary
A vasoactive neuropeptide studied through intravenous, inhaled and other specialist routes. Rapid haemodynamic effects make route and monitoring central.
Protocol basis
The page groups evidence by route and refuses to collapse monitored infusion or inhalation studies into a single self-directed injection schedule.
Community provenance (Peppys)
An authenticated research-forum archive describes vasoactive intestinal peptide most often as an evening or nightly agent, given either subcutaneously or, at least as commonly, as an intranasal spray. Subcutaneous reports open low, near 50-100 mcg, because the peptide is a fast vasodilator that can flush within a minute and lower blood pressure, then build toward roughly 125-200 mcg nightly, with heavier users reaching up to 750 mcg per day. A curated overview and a legacy note record the intranasal method separately, around 50 mcg per spray up to four times daily in a 12 mL applicator, tapered toward zero over 30-90 days. The same archive notes an emerging cancer caveat and conflicting quantities. Usernames are omitted and figures are logged as community provenance without endorsement; subcutaneous, intranasal and nebulised routes are kept separate. The planner above reproduces the arithmetic of the subcutaneous reports only; it does not validate them.
What remains uncertain
A general indication, route-equivalent exposure, long-term safety and matched retail formulation remain unestablished.
Warnings and contraindications
VIP can affect blood pressure, heart rate, airways and gastrointestinal function.
Intravenous and inhaled protocols are not interchangeable with subcutaneous vials.
Human studies are indication-specific and typically use close physiological monitoring.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.